Investigating risk factors for early-onset colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify both exogenous and endogenous risk factors associated with early-onset colorectal cancer (eoCRC), defined as colorectal cancer diagnosed before the age of 50. It will involve a multicenter, retrospective case-control design, where patients diagnosed with eoCRC within the last two years will be compared to healthy controls matched by age and sex. The study will utilize a semi-quantitative food frequency questionnaire to assess dietary habits and other lifestyle factors that may contribute to the development of eoCRC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All sexes eligible
* (for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)
* (for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.

Exclusion Criteria:

* CRC diagnosed at ≥ 50 years
* Diseases that can modify the dietary regimen (celiac disease, diabetes)
* Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)
* Unable to give written consents and to fill in the electronic questionnaire

Where it's running

• Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital
  Denver, Colorado, United States Recruiting
• Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine
  Chicago, Illinois, United States Recruiting
• Department of Gastrointestinal Surgery, Helsinki University Hospital
  Helsinki, Finland Recruiting
• Department of General, Visceral and Transplant Surgery, Hospital of the University of Munich (LMU)
  Munich, Germany Recruiting
• Gabriela Moslein
  Wuppertal, Germany Recruiting
• Prof Giulia Martina Cavestro, MD PhD
  Milan, Lombardy, Italy Recruiting

Study contacts

• Principal investigator: Giulia Martina Cavestro, MD PhD — IRCCS San Raffaele Scientific Institute
• Study coordinator: Giulia Martina Cavestro, MD PhD
• Email: cavestro.giuliamartina@hsr.it
• Phone: 0226435508

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.